Fortress Biotech, Inc. (FBIO) Stock Forecast
FBIO analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 1 analysts
- Price target
- $5.00 average of analyst targets
- Upside to target
- +167.4% from the latest close
- Next earnings
- November 13, 2026
- 52-week range
- $1.87 – $4.38
FBIO analyst ratings
1 analystsNumber of analysts at each rating.
FBIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
FBIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.27 | −$0.27 | −$0.27 | $0.11 | −345.4% | 1 |
| Current fiscal year (2026) | $2.55 | $2.55 | $2.55 | −$0.07 | +3,742.9% | 1 |
| Next fiscal year (2027) | −$1.00 | −$1.00 | −$1.00 | $2.55 | −139.2% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
FBIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $21.6M | $21.6M | $21.6M | +22.4% | 1 |
| Current fiscal year (2026) | $78.8M | $78.8M | $78.8M | +24.6% | 1 |
| Next fiscal year (2027) | $113.2M | $113.2M | $113.2M | +43.7% | 1 |
FBIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
FBIO revenue: reported and forecast
FBIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.15 | −$0.15 | −$0.15 | −$0.15 | −$0.27 | +80.0% | 0 up · 1 down |
| Current fiscal year (2026) | $2.40 | $2.40 | $2.40 | $2.40 | $2.55 | +6.2% | 1 up · 0 down |
| Next fiscal year (2027) | $0.51 | $0.51 | −$0.50 | −$0.50 | −$1.00 | −298.0% | 0 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
FBIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; FBIO beat in 8 of 12.
What analysts expect from FBIO
1 analysts cover Fortress Biotech; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $5.00, 167.4% above the latest close of $1.87. Analysts expect earnings of $2.55 per share for 2026, +3,742.9% from a year earlier. For 2027 the average estimate is −$1.00 per share on revenue of $113.2 million. Fortress Biotech beat the EPS estimate in 8 of the last 12 quarters.
Related: FBIO income statement, FBIO key metrics, FBIO chart. See the FBIO stock overview for the latest quote and news.
FBIO forecast FAQ
What is Fortress Biotech's price target?
The average analyst price target for Fortress Biotech is $5.00, 167.4% above the latest close of $1.87.
Is Fortress Biotech a buy, hold or sell?
Of 1 analysts covering Fortress Biotech, 1 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Fortress Biotech's EPS forecast?
Analysts forecast $2.55 per share for 2026 (range $2.55 to $2.55); for 2027 the estimate is −$1.00.
What is Fortress Biotech's revenue forecast?
The average revenue estimate for 2026 is $78.8 million, growth of 24.6%; for 2027 it is $113.2 million.
When does Fortress Biotech report earnings?
Fortress Biotech is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
Does Fortress Biotech usually beat earnings estimates?
Fortress Biotech reported EPS at or above the analyst estimate in 8 of the last 12 quarters.